Vera Therapeutics (VERA) Stock Forecast & Price Target

Vera Therapeutics is viewed favorably because Trutakna’s first partial quarter on the market produced $10.3M in net sales versus $4.0M expected, with roughly 700 Patient Start Forms since the July 7 approval and management seeing demand, not just inventory, as the main growth driver going forward. The investment case is further strengthened by ORIGIN 3 data showing a 5.00 mL/min/1.73 m²/yr eGFR slope benefit, a 5.1% versus 17.8% kidney-disease progression rate, and no dialysis, transplant, or death events in the Trutakna arm, supporting a path to full approval expected by mid-2027. Financially, Vera ended 3Q26 with about $384M in cash, cash equivalents, and marketable securities, and management believes that liquidity can fund operations through potential full approval and U.S. commercial launch and beyond.

Vera Therapeutics is facing a difficult commercialization path despite Trutakna’s first-quarter launch revenue of $10M and 700 patient start forms, because the lack of a 3Q26 breakout makes uptake hard to validate and compare. The company’s outlook is pressured by a likely competitive entry around 11/30/26, which could blunt Trutakna adoption and limit near-term catalysts even as management absorbs higher COGS from 15%-20% due to Merck KGaA royalties on net sales. Financially, Vera ended 3Q 2026 with $384M in cash, added $75M from its debt facility, and is not expected to be profitable on a continuing basis until 2029, leaving dilution and additional funding risk elevated.